Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the E.O.R.T.C. breast cancer cooperative group

Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies

“…152 In a Phase II study with metastatic breast cancer patients, the overall response rate of the PLD-treated group (45 to 60 mg/m 2 every 3 to 4 weeks for a maximum of six cycles) was 31% (95% confidence interval, 20% to 43%), 153 comparable to the response rates (25 to 40%) for free DOX at conventional doses (50 to 75 mg/m 2 every 3 weeks) in advanced breast cancer patients with similar characteristics. 154–157 …”

Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies

“…152 In a Phase II study with metastatic breast cancer patients, the overall response rate of the PLD-treated group (45 to 60 mg/m 2 every 3 to 4 weeks for a maximum of six cycles) was 31% (95% confidence interval, 20% to 43%), 153 comparable to the response rates (25 to 40%) for free DOX at conventional doses (50 to 75 mg/m 2 every 3 weeks) in advanced breast cancer patients with similar characteristics. 154–157 …”

Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies

“…152 In a Phase II study with metastatic breast cancer patients, the overall response rate of the PLD-treated group (45 to 60 mg/m 2 every 3 to 4 weeks for a maximum of six cycles) was 31% (95% confidence interval, 20% to 43%), 153 comparable to the response rates (25 to 40%) for free DOX at conventional doses (50 to 75 mg/m 2 every 3 weeks) in advanced breast cancer patients with similar characteristics. 154–157 …”

Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies

“…152 In a Phase II study with metastatic breast cancer patients, the overall response rate of the PLD-treated group (45 to 60 mg/m 2 every 3 to 4 weeks for a maximum of six cycles) was 31% (95% confidence interval, 20% to 43%), 153 comparable to the response rates (25 to 40%) for free DOX at conventional doses (50 to 75 mg/m 2 every 3 weeks) in advanced breast cancer patients with similar characteristics. 154–157 …”